Inspire Medical Systems, Inc.
DB:2DR Stock Report
Inspire Medical Systems Future Growth
Future criteria checks 4/6 Inspire Medical Systems is forecast to grow earnings and revenue by 34% and 16.1% per annum respectively. EPS is expected to grow by 32.8% per annum. Return on equity is forecast to be 8.5% in 3 years.
Key information
34.0%
Earnings growth rate
Medical Equipment earnings growth 14.3% Revenue growth rate 16.1% Future return on equity 8.5% Analyst coverage Good
Last updated 12 Nov 2024
Recent future growth updates
Inspire Medical Systems, Inc. Raises Earnings Guidance for the Year 2024 Nov 05
Forecast to breakeven in 2024 Jul 30
Inspire Medical Systems, Inc. Revises Earnings Guidance for the Year 2024 Jul 29
Forecast breakeven date moved forward to 2024 May 11
Inspire Medical Systems, Inc. Revises Financial Guidance for the Full Year 2024 May 08
Inspire Medical Systems, Inc. Reaffirms Revenue Guidance for the Full Year 2024 Feb 07
Show all updates
New minor risk - Shareholder dilution Nov 06
Inspire Medical Systems, Inc. Raises Earnings Guidance for the Year 2024 Nov 05
Inspire Medical Systems, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 07
Inspire Medical Systems, Inc. (NYSE:INSP) announces an Equity Buyback for $150 million worth of its shares. Aug 08 Inspire Medical Systems, Inc. (NYSE:INSP) announces an Equity Buyback for $150 million worth of its shares. Aug 07
Second quarter 2024 earnings released: EPS: US$0.33 (vs US$0.41 loss in 2Q 2023) Aug 07
Inspire Medical Systems, Inc. Announces FD Approval of the Inspire V System Aug 02
Forecast to breakeven in 2024 Jul 30
Inspire Medical Systems, Inc. Revises Earnings Guidance for the Year 2024 Jul 29
Inspire Medical Systems, Inc. Announces Appointment of Melissa J. Mann as Chief People Officer Jul 23
Inspire Medical Systems, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 04
Forecast breakeven date moved forward to 2024 May 11
Now 38% undervalued after recent price drop May 09
First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.53 loss in 1Q 2023) May 08
Inspire Medical Systems, Inc. Revises Financial Guidance for the Full Year 2024 May 08
Now 21% undervalued Apr 12
Inspire Medical Systems, Inc. to Report Q1, 2024 Results on May 07, 2024 Apr 03
New minor risk - Shareholder dilution Mar 20
Full year 2023 earnings released: US$0.72 loss per share (vs US$1.60 loss in FY 2022) Feb 07
Inspire Medical Systems, Inc. Reaffirms Revenue Guidance for the Full Year 2024 Feb 07
Inspire Medical Systems, Inc. Announces Board Retirements Feb 05
Inspire Medical Systems, Inc., Annual General Meeting, May 02, 2024 Jan 27 Inspire Medical Systems, Inc. Announces Jerry C. Griffin, M.D. from Its Board of Directors, Effective on May 2, 2024
Inspire Medical Systems, Inc. to Report Q4, 2023 Results on Feb 06, 2024 Jan 10
Forecast to breakeven in 2025 Jan 09
Inspire Medical Systems, Inc. to Report Fiscal Year 2023 Results on Jan 08, 2024 Jan 09
Inspire Medical Systems, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Full Year 2024 Jan 08
Inspire Medical Systems, Inc. Announces Appointment of Myriam J. Curet as Independent Director Dec 28 Gainey McKenna & Egleston Announces A Class Action Lawsuit Filed Against Inspire Medical Systems Inc Dec 27
New minor risk - Shareholder dilution Nov 09
Inspire Medical Systems, Inc. Revises Revenue Guidance for the Full Year 2023 Nov 08
Third quarter 2023 earnings released: US$0.29 loss per share (vs US$0.60 loss in 3Q 2022) Nov 08
Now 22% undervalued after recent price drop Nov 08
Insufficient new directors Nov 01
New minor risk - Share price stability Oct 12
Now 29% undervalued after recent price drop Oct 12
Inspire Medical Systems, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 05
Second quarter 2023 earnings released: US$0.41 loss per share (vs US$0.53 loss in 2Q 2022) Aug 02
Inspire Medical Systems, Inc. Announces the Addition of Charisse Y. Sparks, M.D., as Chief Medical Officer Aug 01
Inspire Medical Systems, Inc. Appoints Carlton Weatherby as Chief Strategy Officer Jul 25
Inspire Medical Systems, Inc. to Report Q2, 2023 Results on Aug 01, 2023 Jul 06
Inspire Medical Systems, Inc.(NYSE:INSP) dropped from Russell 2000 Dynamic Index Jun 25
First quarter 2023 earnings released: US$0.53 loss per share (vs US$0.61 loss in 1Q 2022) May 03
Full year 2022 earnings released: US$1.60 loss per share (vs US$1.54 loss in FY 2021) Feb 09
Forecast to breakeven in 2025 Feb 09
Inspire Medical Systems, Inc. Provides Revenue Guidance for the Full Year 2023 Feb 08
Inspire Medical Systems, Inc. to Report Q4, 2022 Results on Feb 07, 2023 Jan 11 Inspire Medical Systems, Inc. to Report Fiscal Year 2022 Results on Feb 07, 2023
Third quarter 2022 earnings released: US$0.60 loss per share (vs US$0.38 loss in 3Q 2021) Nov 03
Inspire Medical Systems, Inc. Updates Revenue Guidance for the Full Year of 2022 Nov 02
Inspire Medical Systems, Inc. to Report Q3, 2022 Results on Nov 01, 2022 Oct 05
Inspire Medical Systems, Inc. has completed a Follow-on Equity Offering in the amount of $215 million. Aug 13
Second quarter 2022 earnings released: US$0.53 loss per share (vs US$0.48 loss in 2Q 2021) Aug 03 Inspire Medical Systems, Inc. Revises Earnings Guidance for Full Year 2022
Inspire Medical Systems, Inc. Announces Appointment of Two New Independent Directors to Its Board Aug 02
Inspire Medical Systems, Inc. Announces United States Food and Drug Administration Approval of Expanded, Full-Body MRI Compatibility with Inspire Therapy Jul 07
Inspire Medical Systems, Inc. to Report Q2, 2022 Results on Aug 02, 2022 Jul 06
First quarter 2022 earnings released: US$0.61 loss per share (vs US$0.60 loss in 1Q 2021) May 05
Inspire Medical Systems, Inc. Revises Revenue Guidance for the Year 2022 May 04
Inspire Medical Systems, Inc. to Report Q1, 2022 Results on May 03, 2022 Apr 06
Inspire Medical Systems, Inc. Provides Revenue Guidance for the Full Year 2022 Feb 10
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 09
Third quarter 2021 earnings released: US$0.38 loss per share (vs US$0.39 loss in 3Q 2020) Nov 04
Inspire Medical Systems, Inc. Provides Revenue Guidance for the Full Year 2021 Aug 05
Second quarter 2021 earnings released: US$0.48 loss per share (vs US$0.88 loss in 2Q 2020) Aug 04
Inspire Medical Systems, Inc. Announces Positive Coverage Policy Issued by Anthem for Inspire Therapy May 21
First quarter 2021 earnings released: US$0.60 loss per share (vs US$0.67 loss in 1Q 2020) May 07
Inspire Medical Systems, Inc. Provides Revenue Guidance for the Full Year 2021 May 05
Inspire Medical Systems, Inc., Annual General Meeting, Apr 29, 2021 Mar 17
Inspire Medical Systems, Inc. Announces FDA Approval of Two-Incision Implant Procedure Mar 16
Revenue beats expectations Feb 25
Full year 2020 earnings released: US$2.19 loss per share (vs US$1.40 loss in FY 2019) Feb 25
New 90-day high: €189 Feb 12 Inspire Medical Systems, Inc. to Report Q4, 2020 Results on Feb 23, 2021
New 90-day high: €176 Jan 15
New 90-day high: €154 Nov 25
Inspire Medical Systems, Inc. Announces Full Integration of Inspire Therapy into German DRG Reimbursement System to Begin in 2021 Nov 10
New 90-day high: €140 Nov 05
Third quarter 2020 earnings released: US$0.39 loss per share Nov 05
Revenue beats expectations Nov 05
Inspire Medical Systems, Inc. to Report Q3, 2020 Results on Nov 02, 2020 Sep 30
New 90-day high: €111 Sep 28
New 90-day high - €105 Sep 11
Independent Director recently sold €2.8m worth of stock Aug 30
New 90-day high - €95.50 Aug 25
New 90-day high - €89.00 Aug 06
First half earnings released Aug 06
Inspire Medical Systems, Inc. to Report Q2, 2020 Results on Aug 04, 2020 Jul 08
Earnings and Revenue Growth Forecasts DB:2DR - Analysts future estimates and past financials data (USD Millions) Date Revenue Earnings Free Cash Flow Cash from Op Avg. No. Analysts 12/31/2026 1,123 88 207 207 13 12/31/2025 950 59 167 164 17 12/31/2024 796 40 128 107 17 9/30/2024 756 33 38 78 N/A 6/30/2024 706 6 -9 30 N/A 3/31/2024 661 -16 3 35 N/A 12/31/2023 625 -21 1 25 N/A 9/30/2023 570 -33 8 27 N/A 6/30/2023 526 -41 19 34 N/A 3/31/2023 466 -44 11 23 N/A 12/31/2022 408 -45 2 12 N/A 9/30/2022 348 -50 -14 -7 N/A 6/30/2022 301 -44 -23 -18 N/A 3/31/2022 262 -43 -27 -22 N/A 12/31/2021 233 -42 -25 -20 N/A 9/30/2021 201 -47 -30 -25 N/A 6/30/2021 175 -47 -38 -34 N/A 3/31/2021 134 -57 -52 -49 N/A 12/31/2020 115 -57 -55 -53 N/A 9/30/2020 96 -59 -57 -55 N/A 6/30/2020 81 -57 -51 -49 N/A 3/31/2020 87 -41 -39 -37 N/A 12/31/2019 82 -33 -36 -33 N/A 9/30/2019 72 -29 -32 -29 N/A 6/30/2019 64 -25 -31 -30 N/A 3/31/2019 57 -24 -24 -23 N/A 12/31/2018 51 -22 -19 -19 N/A 9/30/2018 44 -21 -20 -19 N/A 6/30/2018 38 -21 N/A -19 N/A 3/31/2018 33 -20 N/A -17 N/A 12/31/2017 29 -18 N/A -16 N/A 12/31/2016 16 -19 N/A -18 N/A 12/31/2015 8 -21 N/A -22 N/A
Show more
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2DR's forecast earnings growth (34% per year) is above the savings rate (1%).
Earnings vs Market: 2DR's earnings (34% per year) are forecast to grow faster than the German market (20.6% per year).
High Growth Earnings: 2DR's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 2DR's revenue (16.1% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 2DR's revenue (16.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2DR's Return on Equity is forecast to be low in 3 years time (8.5%).
Discover growth companies Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}